BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The clinical objective of this study was to determine the effect of BIRB 796 BS on
pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population
pharmacokinetics of BIRB 796 BS and to determine the safety of BIRB 796 BS over 4 weeks of
treatment in patients with moderate to severe plaque-type psoriasis.